Company profile
ROCKWELL MEDICAL, INC.
NASDAQ:RMTIBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Calcitriol | approved | — | 0 | — |
| FERRIC PYROPHOSPHATE CITRATE | approved | — | 12 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (19)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01920854 | phase1 | completed | 2013-06-01 | 2013-09-01 | Rockwell Medical Technologies, Inc. | A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers. |
| NCT04042324 | phase1_2 | completed | 2019-09-30 | 2020-01-16 | Rockwell Medical Technologies, Inc. | A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients |
| NCT01320202 | phase3 | completed | 2011-03-01 | 2013-05-01 | Rockwell Medical Technologies, Inc. | Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients |
| NCT01286012 | phase2 | completed | 2011-01-01 | 2013-01-01 | Rockwell Medical Technologies, Inc. | Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients |
| NCT01322347 | phase3 | completed | 2011-04-01 | 2014-01-01 | Rockwell Medical Technologies, Inc. | Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2) |
FDA applications (4)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 076206 | ANDA | ROCKWELL MEDICAL TECHNOLOGIES INC | ||||
Loading… | ||||||
| NDA 206317 | NDA | ROCKWELL MEDICAL INC | ||||
Loading… | ||||||
| NDA 208551 | NDA | ROCKWELL MEDICAL INC | ||||
Loading… | ||||||
| NDA 212860 | NDA | ROCKWELL MEDICAL INC | ||||
Loading… | ||||||